Oxigene (OXGN) says the European Medicines Agency has granted orphan drug status to its ovarian cancer treatment Zybrestat. Data from a Phase 2 trial testing the combination of Zybrestat and Roche's (RHHBY.OB) cancer drug Avastin - to treat advanced ovarian cancer - could be available in early 2014. If the results prove positive, it could provide the basis for a registration program. Shares +32% AH.
Oxigene (OXGN) says the European Medicines Agency has granted orphan drug status to its ovarian...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs